ADHD
Automated Reconstruction of White Matter Pathways in Attention-Deficit / Hyperactivity Disorder Using Anatomical Priors
Christienne Gonzales Damatac, Marcel Zwiers, Barbara Franke, Jan Buitelaar, Christian Beckmann, Emma Sprooten (May 2018)
ADHD has repeatedly been associated with alterations in white matter microstructure, as measured through fractional anisotropy (FA) and acquired through diffusion-weighted MRI (DWI). Due to methodological heterogeneity of analysis techniques, there have been inconsistent results regarding anatomical specificity of changes in FA. The aim of this study was to determine, in an automated manner, whether FA is related to ADHD in a large cohort of patients and healthy controls.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Endocannabinoid Signaling in the Control of Social Behavior
Don Wei, Stephen Allsop, Kay Tye, Daniele Piomelli (May 2017)
Mechanistic studies in animal models have revealed important roles for the endocannabinoid signaling system, comprising G protein-coupledcannabinoid receptors and their endogenous lipid-derived agonists, in the control of neural processes that underpin social anxiety and social reward, two key aspects of social behavior. An emergent insight from these studies is that endocannabinoid signaling in specific circuits of the brain is context dependent and selectively recruited.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Lifelong imbalanced LA/ALA intake impairs emotional and cognitive behavior via changes in brain endocannabinoid system
Erica Zamberletti, Fabiana Piscitelli, Valentina De Castro, Elisabetta Murru, Marina Gabaglio, Paola Colucci, Chiara Fanali, Pamela Prini, Tiziana Bisogno, Mauro Maccarrone, Patrizia Campolongo, Sebastiano Banni, Tiziana Rubino and Daniela Parolaro (April 2016)
Imbalanced dietary n-3 and n-6 PUFA content has been associated with a number of neurological conditions. Endocannabinoids are n-6 PUFA derivatives, whose brain concentrations are sensitive to modifications of fatty acid composition of the diet and play a central role in the regulation of mood and cognition. As such, the endocannabinoid system appears to be an ideal candidate for mediating the effects of dietary fatty acids on mood and cognition.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Treating ADHD with Cannabinoids
By Cornerstone Staff (June 2014)
New research has begun to suggest that the body’s cannabinoid system, specifically cannabinoid agonists like those found in cannabis, may play a role in treatment. At this time, researchers observed that SHR’s had lower CB1 cannabinoid receptor densities in pre-frontal cortex regions than their WKY rat (normal rat) counter-parts. This finding triggered an important question: if impulsivity is associated with a lack of density in CB1 receptors, could increasing the amount of cannabinoids that bind to those receptors make up for that lack of density and therefore reverse some of the impulsivity?
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.